Osteopore Expands into China with Exclusive RMB 12m Deal
Osteopore Limited has secured an exclusive multi-year distribution agreement with Majeton to commercialise its dental and maxillofacial products in China, Hong Kong, and Macau, marking a major step in its Asia-Pacific expansion.
- Exclusive distribution deal valued above RMB 12 million with Majeton
- Focus on dental, orthodontic, and maxillofacial surgery markets
- Partnership leverages Majeton’s parent company Essex Bio-Technology’s extensive network
- Deal includes upfront and milestone payments tied to sales and regulatory progress
- Targets a rapidly growing Chinese dental biomaterials market expected to reach USD 530 million by 2030
Strategic Expansion into China
Osteopore Limited, an Australian-Singaporean regenerative medicine company specialising in 3D-printed biomimetic and bioresorbable implants, has taken a significant leap in its international growth strategy. The company announced an exclusive multi-year distribution agreement with Majeton Pte Ltd, a subsidiary of Hong Kong-listed Essex Bio-Technology Limited, to commercialise its dental, orthodontic, and maxillofacial surgery products across China, Hong Kong, and Macau.
This deal, valued at over RMB 12 million, is structured with upfront and milestone payments, reflecting confidence in Osteopore’s innovative product line and the potential of the Chinese market. The partnership aligns with Osteopore’s approach of collaborating with established regional players to accelerate commercialisation and broaden its footprint in the Asia-Pacific healthcare sector.
Leveraging Established Networks
Majeton, known for distributing therapeutics, medical devices, and nutraceuticals throughout Southeast Asia, will utilise its parent company Essex Bio-Technology’s extensive network to facilitate market access. Essex Bio-Technology is a well-regarded bio-pharmaceutical company with a strong presence in over 13,500 hospitals and 43 regional sales offices across China. Its proven track record, including multiple appearances on Forbes Asia's Best Under A Billion list, provides Osteopore with a robust platform to reach dental and surgical professionals effectively.
Osteopore’s patented 3D-printed scaffolds are designed to promote natural bone healing and reduce complications associated with permanent implants. The company’s products have received positive clinical feedback, particularly in vertical bone augmentation, a key area in dental and maxillofacial surgery.
Market Potential and Growth Outlook
The Chinese dental bone graft substitute and membrane market was valued at USD 212 million in 2023 and is forecast to grow at a compound annual growth rate of 14%, reaching an estimated USD 530 million by 2030. Osteopore’s entry into this market through a trusted local partner positions it well to capture a meaningful share of this expanding sector.
CEO Dr Lim Yujing expressed optimism about the partnership, highlighting the shared commitment to innovation and excellence. The collaboration is expected to not only drive commercial success but also contribute positively to patient outcomes and the broader healthcare ecosystem.
Looking Ahead
While the agreement sets a promising foundation, the real test will be in achieving regulatory approvals and meeting sales milestones that trigger further payments. Osteopore’s ability to navigate the competitive landscape and regulatory environment in China will be critical to unlocking the full potential of this deal.
Bottom Line?
Osteopore’s partnership with Majeton marks a pivotal step into China’s booming dental biomaterials market, with future milestones poised to shape its regional success.
Questions in the middle?
- How quickly will Osteopore achieve regulatory approvals in China, Hong Kong, and Macau?
- What are the projected sales targets tied to milestone payments in the agreement?
- How will Osteopore differentiate itself amid competition in the Chinese dental biomaterials market?
